THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqGM:RPRX) today announced financial results for the three-months ended March 31, 2007. Financial Results Total revenues for the three-month period ended March 31, 2007 were $318,000 as compared to $174,000 for the same period in the prior year. Interest income increased 83% to $318,000 for the three-month period ended March 31, 2007 as compared to $174,000 for the same period in the prior year primarily due to an increase in marketable securities as a result of the completion of the Company’s follow-on public offering on February 5, 2007 in which the Company received approximately $33.0 million in net proceeds.
